This week key colleagues from Parkinson's UK met with the UK Medicines and Healthcare products Regulatory Agency (MHRA) along with colleagues from University College London and the British Generics Manufacturers Association (BGMA).

We met to discuss an upcoming trial of a drug, funded through the Parkinson's Virtual Biotech, which we hope to repurpose to help manage a...

Results from a study looking at an experimental drug to tackle the debilitating side effect of dyskinesia, have offered hope that it may have potential as a future treatment for people with Parkinson’s.

Research carried out by US biotech company Neurolixis with funding from Parkinson’s UK, investigated the effect of the drug NLX-112 on dyskinesia, a common side effect...

Parkinson’s UK is pleased to announce the release of the next tranche of funding to continue our collaboration with NRG Therapeutics Ltd to develop novel drugs that can protect mitochondria and thereby slow the progression of Parkinson’s.  
 
Mitochondria are tiny batteries present inside cells that provide the essential energy they need to survive and function. Prev...

Parkinson's Foundation grants £200,000 to Parkinson's UK to invest in the Parkinson's Virtual Biotech.

Each year, Parkinson's UK, their supporters and partners invest more than £4 million into the Parkinson's Virtual Biotech to rapidly develop and test the most promising research findings with the aim of turning them into treatments that will transform the lives of pe...

The Parkinson’s Virtual Biotech is pleased to announce the appointment of eminent expert Dr Richard Seabrook PhD MBA as a non-executive Director of NRG Therapeutics.

Richard brings over 25 years of experience in scientific translation working with companies, charities and universities to accelerate drug development. 

During his time at The Wellcome Trust Richard establ...

A pioneering clinical trial will investigate the use of cannabidiol (CBD) - a compound found in the cannabis plant - in people with Parkinson’s-related psychosis.

Parkinson’s UK, the largest charitable funder of Parkinson's research in Europe, is partnering with scientists at King’s College London and investing £1.2 million in the phase II clinical trial. 

This is the...